Opko Health, Inc. OPK
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About OPK
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
OPKO Health, Inc. is a diversified healthcare company operating across the biotechnology, diagnostics, and pharmaceutical industries. The company develops and commercializes diagnostic tests, specialty pharmaceuticals, biologics, and healthcare services, with operations spanning clinical laboratories, drug development, and medical technologies. OPKO’s primary revenue drivers have historically included laboratory testing services through BioReference Health, pharmaceutical products such as Rayaldee, and licensing or collaboration arrangements tied to its biologics pipeline. The company serves physicians, hospitals, healthcare systems, clinical researchers, and patients across multiple therapeutic categories, including endocrinology, nephrology, infectious disease, and oncology.
The company was founded in 1991 and is headquartered in Miami, Florida. OPKO evolved through a series of acquisitions and strategic investments that expanded its footprint beyond pharmaceutical development into diagnostics and laboratory services. A major milestone was the acquisition of Bio-Reference Laboratories in 2015, which significantly increased OPKO’s scale in diagnostic testing and healthcare services. The company has also pursued partnerships with larger pharmaceutical firms to advance drug candidates and biologics, positioning itself as an integrated healthcare company with exposure to both recurring diagnostic revenue and long-term pharmaceutical development opportunities.
Business Operations
OPKO operates through several major business lines, including Diagnostics, Pharmaceuticals, and healthcare-related technologies and services. The diagnostics segment is anchored by BioReference Health, one of the larger full-service clinical laboratory businesses in the United States, providing oncology testing, women’s health diagnostics, urology testing, and clinical laboratory services. The pharmaceuticals and biologics business includes products and development programs focused on endocrinology, nephrology, infectious diseases, and hormone therapies. Revenue is generated through laboratory testing fees, pharmaceutical product sales, licensing agreements, milestone payments, and research collaborations.
The company maintains operations in both domestic and international markets, with substantial activities in the United States, parts of Europe, Latin America, and Israel. OPKO controls various proprietary diagnostic technologies, intellectual property portfolios, and biologic development assets. Strategic partnerships have included collaborations with major pharmaceutical companies such as Pfizer for hormone-related therapeutics and other development-stage biologics. Subsidiaries and affiliated operations include BioReference Health, 4Kscore, and other healthcare and diagnostic entities tied to laboratory services and specialty testing.
Strategic Position & Investments
OPKO’s strategic direction has centered on expanding high-value diagnostic testing, advancing specialty pharmaceutical assets, and leveraging partnerships to reduce development risk. The company has invested significantly in diagnostics infrastructure, molecular testing capabilities, and biologic therapies targeting chronic diseases and hormone deficiencies. Its strategy has also emphasized monetizing intellectual property through licensing agreements and co-development arrangements with larger healthcare companies.
Key investments and acquisitions have included the purchase of Bio-Reference Laboratories, which substantially expanded OPKO’s diagnostics platform, as well as investments in specialty pharmaceutical and medical technology businesses. OPKO has also pursued emerging opportunities in precision diagnostics, molecular testing, and long-acting biologics. The company’s portfolio has included development-stage technologies related to endocrinology, renal disease management, and infectious disease testing. Public disclosures and filings indicate continued focus on operational efficiency within laboratory services while maintaining selective investment in pharmaceutical pipeline assets.
Geographic Footprint
OPKO is headquartered in Miami, Florida, and maintains a broad operational footprint across the United States, where the majority of its laboratory and healthcare service activities are concentrated. Through BioReference Health, the company operates laboratory facilities, patient service centers, and diagnostic networks serving healthcare providers nationwide. The company also maintains research, development, and business operations in Israel and selected international markets.
Outside the United States, OPKO has maintained activities and investments in parts of Europe, Latin America, and other international healthcare markets through subsidiaries, partnerships, and licensing arrangements. Its international presence has historically supported pharmaceutical development, diagnostics commercialization, and strategic collaborations. The company’s global activities remain smaller in scale relative to its U.S. diagnostics operations but contribute to its broader biotechnology and pharmaceutical development strategy.
Leadership & Governance
OPKO’s leadership structure combines healthcare industry, biotechnology, diagnostics, and investment experience. The company has historically been closely associated with founder and longtime executive leadership focused on acquisitions, diagnostics expansion, and pharmaceutical development. Strategic priorities communicated through public filings and investor communications have emphasized diversification across diagnostics and therapeutics while pursuing operational discipline and long-term asset development.
Key executives include:
- Phillip Frost, M.D. – Chairman and Chief Executive Officer
- Adam Logal – Senior Vice President and Chief Financial Officer
- Jon R. Cohen, M.D. – Executive Chairman of BioReference Health
- Brian McDonough – President of BioReference Health
- Richard Lerner, M.D. – Executive Vice President, Clinical Sciences
Leadership strategy has generally focused on integrating diagnostics with pharmaceutical innovation, expanding specialty testing capabilities, and developing strategic partnerships to support commercialization and clinical development activities.